Drug intelligence / Profile preview

mertiatide

Development stage
Unknown
Lead developer
Curium
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules, Peptides
Administration
Intravenous
01

Overview

Mertiatide (specifically as technetium Tc 99m mertiatide, also known as 99mTc-MAG3) is a diagnostic radiopharmaceutical used in nuclear medicine for renal imaging. It is prepared from a kit containing the precursor betiatide, which is reconstituted with sodium pertechnetate Tc 99m to form the active technetium complex. Following intravenous administration, technetium Tc 99m mertiatide is rapidly cleared from the blood by the kidneys, primarily via active renal tubular secretion mediated by organic anion transporters (OAT1 and OAT3) and apical efflux transporters (MRP2 and MRP4). This rapid and specific renal clearance allows for the scintigraphic evaluation of renal function, split function, renal perfusion, and the diagnosis of congenital or acquired renal abnormalities, renal failure, urinary tract obstruction, and calculi in both adult and pediatric patients.

Brand names
IELMAG3IELMAG-3IELMAG 3Technescan MAG3
Other names
99mTc-MAG399mTc-mercaptoacetyltriglycineMAG 3MAG3MAG-3mercaptoacetyltriglycinetechnetium (99mTc) mertiatidetechnetium Tc 99m mertiatidetechnetium-99m-mercaptoacetyltriglycinetechnetium99m-mercaptoacetyltriglycinetechnetium 99m-mercaptoacetyltriglycine

Beyond the preview

Go deeper on mertiatide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on mertiatide.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call